en · de · es · fr · pt
aod-9604-notes.peptides6908.com › Guide › Identity And Molecular Context — Background and Details

Identity And Molecular Context — Background and Details

By Editorial Desk · published 2026-07-22 · last reviewed 2026-08-01 · Guide

Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity and Molecular Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from a fragment of human growth hormone
Sequence basishGH residues 176-191Commonly described as a 16-amino-acid fragment
AppearanceWhite to off-white powderTypical for lyophilized research peptides
SolubilitySoluble in water or aqueous bufferExact solubility depends on pH and purity
Common synonymsAOD9604; hGH 176-191Spelling and punctuation vary across sources

Background And Research Context

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Related pages on this site

Regulation and Detection Context

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

Background from the literature

To avoid transfusion reactions, the donor and recipient blood are tested, typically ordered as a "type and screen" for the recipient. The "type" in this case is the ABO and Rh type, specifically the phenotype, and the "screen" refers to testing for atypical antibodies that might cause transfusion problems. The typing and screening are also performed on donor blood. The blood groups represent antigens on the surface of the red blood cells which might react with antibodies in the recipient. The ABO blood group system has four basic phenotypes: O, A, B, and AB. In the former Soviet Union these were called I, II, III, and IV, respectively. There are two important antigens in the system: A and B. Red cells without A or B are called type O, and red cells with both are called AB. Except in unusual cases like infants or seriously immunocompromised individuals, all people will have antibodies to any ABO blood type that isn't present on their own red blood cells, and will have an immediate hemolytic reaction to a unit that is not compatible with their ABO type. In addition to the A and B antigens, there are rare variations which can further complicate transfusions, such as the Bombay phenotype. The Rh blood group system consists of around 50 different antigens, but that of the greatest clinical interest is the "D" antigen, though it has other names and is commonly just called "negative" or "positive". Unlike the ABO antigens, a recipient will not usually react to the first incompatible transfusion because the adaptive immune system does not immediately recognize it.

== Signs and symptoms == Obesity is the chief symptom of HAIR-AN. In the majority of young women affected by HAIR-AN, hyperandrogenism leads to oily skin, acne, hirsutism, menstrual irregularities and, in some cases, androgenic alopecia, clitoromegaly, changes in muscle mass and deepening of the voice. Insulin resistance can be accompanied by normal or elevated levels of glucose. Symptoms of diabetes such as polydipsia, polyuria and weight loss may sometimes be present.

Acting on the nuclear mineralocorticoid receptors (MR) within the principal cells of the distal tubule and the collecting duct of the kidney nephron, it upregulates and activates the basolateral Na+/K+ pumps, which pumps three sodium ions out of the cell, into the interstitial fluid and two potassium ions into the cell from the interstitial fluid. This creates a concentration gradient which results in reabsorption of sodium (Na+) ions and water (which follows sodium) into the blood, and secreting potassium (K+) ions into the urine (lumen of collecting duct). Aldosterone upregulates epithelial sodium channels (ENaCs) in the collecting duct and the colon, increasing apical membrane permeability for Na+ and thus absorption. Cl− is reabsorbed in conjunction with sodium cations to maintain the system's electrochemical balance. Aldosterone stimulates the secretion of K+ into the tubular lumen. Aldosterone stimulates Na+ and water reabsorption from the gut, salivary and sweat glands in exchange for K+. Aldosterone stimulates secretion of H+ via the H+/ATPase in the intercalated cells of the cortical collecting tubules Aldosterone upregulates expression of NCC in the distal convoluted tubule chronically and its activity acutely. Aldosterone is responsible for the reabsorption of about 2% of filtered sodium in the kidneys, which is nearly equal to the entire sodium content in human blood under normal glomerular filtration rates. Aldosterone, probably acting through mineralocorticoid receptors, may positively influence neurogenesis in the dentate gyrus.

Sources: en.wikipedia.org

Further detail

The light source shines onto or through the sample. The sample transmits or reflects light. The detector detects how much light was reflected from or transmitted through the sample. The detector then converts how much light the sample transmitted or reflected into a number.

excessive water consumption; this condition is often called polydipsia. frequent and/or excessive urination, known as polyuria, often requiring the dog to be let outside to urinate during the night, abnormal increase in appetite, a condition known as polyphagia., weight loss; dogs with diabetes may also suffer from severe weight loss, weakness, anorexia and blindness. Sometimes, the first sign of diabetes noticed by the owner may be that their dog either has become blind (due to the formation of cataracts in the eyes), or has vomiting, anorexia, lethargy and weakness (due to ketoacidosis).

CIVIL RECORDS Held in the 20 arrondissement town halls: Births from 1925 to the present. Marriages from 1948 to the present. Deaths from 1987 to the present. Available at the Paris Archives: Before 1860: Births, marriages, and deaths from the 16th century to 1859—alphabetical-chronological indexes and records of the so-called “reconstructed” civil status from former parishes of Paris, the 12 former arrondissements, and fully or partially annexed communes in 1860. From 1860 onwards: Decennial tables: Births, marriages, and deaths up to 1932. Marriages from 1955 to 1974. Deaths from 1955 to 1984. Annual tables: Marriages from 1933 to 1954 (only record numbers are listed). Deaths from 1933 to 1954 (only record numbers are listed) and from 1985–1986. Records: Births up to 1922. Marriages up to 1947. Deaths up to 1986. Available on-site at the Paris Archives: Records from the second reconstruction (V.5.E). 29 registers of parish or civil status records from the 18th and 19th centuries not destroyed in 1871 (V.6.E 1–29). Births from 1923 and 1924. CATHOLIC RECORDS Baptisms, marriages, and burials from the 16th century to 1792—about 50 parish registers, mostly containing excerpts, preserved at the National Archives and the National Library. Baptisms, marriages, and burials from all Parisian churches from 1793 to 1909 (with gaps): First copies preserved in parishes (a single register for burials). Second copies (baptisms and marriages only) deposited at the Paris Archives by the Archdiocese.

==== Sexual maturity ==== Cephalopods that are sexually mature and of adult size begin spawning and reproducing. After the transfer of genetic material to the following generation, the adult cephalopods in most species then die. Sexual maturation in male and female cephalopods can be observed internally by the enlargement of gonads and accessory glands. Mating would be a poor indicator of sexual maturation in females; they can receive sperm when not fully reproductively mature and store them until they are ready to fertilize the eggs. Males are more aggressive in their pre-mating competition when in the presence of immature females than when competing for a sexually mature female. Most cephalopod males develop a hectocotylus, an arm tip which is capable of transferring their spermatozoa into the female mantle cavity. Though not all species use a hectocotylus; for example, the adult nautilus releases a spadix. Some male squids, mainly deep-water species, have instead evolved a penis longer than their own body length, the longest penis in any free-living animals. It is assumed these males simply attach a spermatophore anywhere on a female's body. An indication of sexual maturity of females is the development of brachial photophores to attract mates.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

What is the exact length of AOD-9604?

It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.

Does AOD-9604 occur naturally?

It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Network